𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

✍ Scribed by Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
395 KB
Volume
15
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis

Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated.

Methods:

We studied MH during long-term treatment with IFX in 214 CD patients. A total of 183 patients (85.5%) responded to induction therapy and 31 patients (14.5%) were primary nonresponders. They underwent lower gastrointestinal (GI) endoscopy within a median of 0.7 months (interquartile range [IQR] 0.1-6.8) prior to first IFX and after a median of 6.7 months (IQR 1.4-24.6) after start of IFX and were further analyzed. The relationship between the outcome of IFX treatment long-term and MH was studied.

Results: MH was observed in 67.8% of the 183 initial responders (n ¼ 124), with 83 patients having complete healing (45.4%) and 41 having partial healing (22.4%). Scheduled IFX treatment from the start resulted in MH more frequently (76.9% MH rate) than episodic treatment (61.0% MH rate; P ¼ 0.0222, odds ratio [OR] 2.14, 95% confidence interval [CI] 1.11-4.12). Concomitant treatment with corticosteroids (CS) had a negative impact on MH (37.9% in patients with CS versus 63.2% in patients without CS; P ¼ 0.021, OR 0.36, 95% CI 0.16-0.80). MH was associated with a significantly lower need for major abdominal surgery (MAS) during long-term follow-up (14.1% of patients with MH needed MAS versus 38.4% of patients without MH; P < 0.0001).

Conclusions: MH induced by long-term maintenance IFX treatment is associated with an improved long-term outcome of the disease especially with a lower need for major abdominal surgeries.

📜 SIMILAR VOLUMES

Long-term outcome of maintenance inflixi
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease
✍ Jeffrey S. Hyams; Trudy Lerer; Anne Griffiths; Marian Pfefferkorn; Subra Kugatha 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 1 views

Background: Infliximab therapy has short-term benefits in children with moderate-to-severe Crohn's disease (CD). We assessed the long-term outcome of infliximab maintenance therapy in children with CD. ## Methods: We performed a multicenter cohort study of 729 pediatric patients with CD enrolled i

Impact of prior irregular infliximab dos
Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease
✍ Daniel J. Stein; Ashwin N. Ananthakrishnan; Mazen Issa; John B. Williams; Dawn B 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 1 views

## Background: Infliximab is efficacious in the management of moderate to severe crohn's disease (cd). there are limited data regarding performance of infliximab in patients who require reinitiation of maintenance dosing following previous irregular exposure. ## Methods: This was a retrospective,

Immediate and long-term outcomes of cort
Immediate and long-term outcomes of corticosteroid therapy in pediatric crohn's disease patients
✍ Alfreda Krupoves; David R. Mack; Ernest G. Seidman; Colette Deslandres; Vytautas 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 2 views

Background: Although a mainstay of treatment of moderate to severe Crohn's disease (CD), corticosteroids use presents significant challenges because of large interindividual variability in response. Corticosteroid-dependence is of particular concern in children, where high rates have been reported.

Predictive model for the outcome of infl
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
✍ Tibor Hlavaty; Marc Ferrante; Liesbet Henckaerts; Marie Pierik; Paul Rutgeerts; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 1 views

## Background: Infliximab (ifx) is an effective therapy for refractory luminal and fistulizing crohn's disease (cd). predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. we aimed to develop a predictive mode

Impacts of long-term enteral nutrition o
Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: A prospective study
✍ Takayuki Yamamoto; Maki Nakahigashi; Abbi R. Saniabadi; Takashi Iwata; Yasuki Ma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

## Background: Long-term enteral nutrition may maintain clinical and endoscopic remission in patients with crohn's disease (cd). the aim of this prospective study was to investigate the impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal tissue cytokines